- Home
- ISRL vs ZNTL Comparison
ISRL vs ZNTL Comparison
Compare ISRL & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISRL
- ZNTL
- Stock Information
- Founded
- ISRL 2021
- ZNTL 2014
- Country
- ISRL United States
- ZNTL United States
- Employees
- ISRL N/A
- ZNTL N/A
- Industry
- ISRL Blank Checks
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- ISRL Finance
- ZNTL Health Care
- Exchange
- ISRL Nasdaq
- ZNTL Nasdaq
- Market Cap
- ISRL 146.3M
- ZNTL 134.7M
- IPO Year
- ISRL 2023
- ZNTL 2020
- Fundamental
- Price
- ISRL $11.40
- ZNTL $2.32
- Analyst Decision
- ISRL
- ZNTL Buy
- Analyst Count
- ISRL 0
- ZNTL 8
- Target Price
- ISRL N/A
- ZNTL $8.53
- AVG Volume (30 Days)
- ISRL 1.1K
- ZNTL 2.6M
- Earning Date
- ISRL 01-01-0001
- ZNTL 03-04-2025
- Dividend Yield
- ISRL N/A
- ZNTL N/A
- EPS Growth
- ISRL N/A
- ZNTL N/A
- EPS
- ISRL 0.26
- ZNTL N/A
- Revenue
- ISRL N/A
- ZNTL $40,560,000.00
- Revenue This Year
- ISRL N/A
- ZNTL N/A
- Revenue Next Year
- ISRL N/A
- ZNTL N/A
- P/E Ratio
- ISRL $43.68
- ZNTL N/A
- Revenue Growth
- ISRL N/A
- ZNTL N/A
- 52 Week Low
- ISRL $10.73
- ZNTL $1.61
- 52 Week High
- ISRL $11.58
- ZNTL $18.07
- Technical
- Relative Strength Index (RSI)
- ISRL 50.09
- ZNTL 49.24
- Support Level
- ISRL $11.43
- ZNTL $2.37
- Resistance Level
- ISRL $11.58
- ZNTL $2.36
- Average True Range (ATR)
- ISRL 0.00
- ZNTL 0.25
- MACD
- ISRL -0.01
- ZNTL 0.08
- Stochastic Oscillator
- ISRL 40.00
- ZNTL 69.27
About ISRL Israel Acquisitions Corp
Israel Acquisitions Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.